Cepheid Q4 Revenues Rise 71 Percent as It Trims Net Loss | GenomeWeb
This article has been updated to include comments from a conference call and a stock quote.
 
NEW YORK (GenomeWeb News) – Cepheid reported today that its fourth-quarter revenues rose 71 percent, driven by increasing adoption of its GeneXpert system among hospitals outside of the Veterans Administration system, as the firm cut its net loss 36 percent year over year.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.